<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/671"/><api:result><api:object category="publication" id="671" last-affected-when="2024-03-15T02:34:33.387+00:00" last-modified-when="2024-03-15T02:34:33.387+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/671" created-when="2010-05-17T13:46:25.233+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-12-03</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1351708" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1016/S0920-1211(99)00065-0" last-modified-when="2022-09-12T00:33:27.34+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0920-1211(99)00065-0</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0920-1211(99)00065-0"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0920-1211(99)00065-0"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0920-1211</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Epilepsy Research</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>12</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1016/s0920-1211(99)00065-0</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>8</api:day><api:month>1</api:month><api:year>2020</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record><api:record format="native" id="95115" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033402130" last-modified-when="2021-06-23T12:54:18.007+01:00"><api:citation-count>55</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Retigabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester, D-23129) is a broad acting anticonvulsant currently undergoing phase II clinical trials. An opening effect on leakage conductance K+ channels, potentiation of GABA induced currents and a weak blocking effect on Na+ and Ca++ channels were previously reported. The goal of this study was to investigate whether retigabine is capable of blocking epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparations and whether the anti-burst activity can be related to the K+ channel opening effect. In the low Ca++ model, synaptic transmission is blocked and discharges evolve from ephaptically-coupled neurons. Compounds which directly interfere with the threshold for action potential induction via alteration of ion channel function (i.e. Na+ channel blocker) may alter the discharges, while compounds interfering with synaptic transmission are not active. Retigabine suppressed the discharges in a concentration-dependent manner. A significant reduction in frequency without effect on amplitude was observed after application of 1 μM, and a full block of all discharges after application of 25 μM. The opener of the ATP sensitive K+ channels cromakalim was also active. Application of 300 μM cromakalim yielded to a lower frequency with no effects on the amplitude of discharges. Treatment with phenytoin and carbamazepine resulted in a marked reduction in amplitude accompanied by a rise in frequency; only at higher concentrations was a full block observed. The effect of retigabine therefore differs from sodium channel blockers and can be related to the K+ channel opening effect. In the low Mg++ model, excitatory neurotransmission is augmented by reducing the Mg++ block of NMDA channels. This results in development of interictal-like epileptiform activity in area CA1 in isolated hippocampal slices. Treatment with retigabine 10 μM resulted in a significant reduction of the discharges, and discharges were fully blocked after application of 25 μM. Qualitatively similar effects were observed with cromakalim and valproate, albeit at higher concentrations. The data indicate that retigabine exerts potent broad spectrum activity making it an interesting candidate for treatment of drug resistant patients. Copyright (C) 2000 Elsevier Science B.V.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Arzneimittelwerk Dresden GmbH</api:line><api:line type="city">Radebeul</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">13610113900</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Arzneimittelwerk Dresden GmbH</api:line><api:line type="city">Radebeul</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">17836161800</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/S0920-1211(99)00065-0</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/S0920-1211(99)00065-0"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/S0920-1211(99)00065-0"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10604606</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0920-1211</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Epilepsy Research</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>3</api:day><api:month>12</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca&lt;sup&gt;++&lt;/sup&gt; and low Mg&lt;sup&gt;++&lt;/sup&gt; model in the hippocampal slice preparation</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record><api:record format="native" id="671" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10604606" last-modified-when="2020-04-29T04:27:49.537+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Retigabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester, D-23129) is a broad acting anticonvulsant currently undergoing phase II clinical trials. An opening effect on leakage conductance K+ channels, potentiation of GABA induced currents and a weak blocking effect on Na+ and Ca++ channels were previously reported. The goal of this study was to investigate whether retigabine is capable of blocking epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparations and whether the anti-burst activity can be related to the K+ channel opening effect. In the low Ca++ model, synaptic transmission is blocked and discharges evolve from ephaptically-coupled neurons. Compounds which directly interfere with the threshold for action potential induction via alteration of ion channel function (i.e. Na+ channel blocker) may alter the discharges, while compounds interfering with synaptic transmission are not active. Retigabine suppressed the discharges in a concentration-dependent manner. A significant reduction in frequency without effect on amplitude was observed after application of 1 microM, and a full block of all discharges after application of 25 microM. The opener of the ATP sensitive K+ channels cromakalim was also active. Application of 300 microM cromakalim yielded to a lower frequency with no effects on the amplitude of discharges. Treatment with phenytoin and carbamazepine resulted in a marked reduction in amplitude accompanied by a rise in frequency; only at higher concentrations was a full block observed. The effect of retigabine therefore differs from sodium channel blockers and can be related to the K+ channel opening effect. In the low Mg++ model, excitatory neurotransmission is augmented by reducing the Mg++ block of NMDA channels. This results in development of interictal-like epileptiform activity in area CA1 in isolated hippocampal slices. Treatment with retigabine 10 microM resulted in a significant reduction of the discharges, and discharges were fully blocked after application of 25 microM. Qualitatively similar effects were observed with cromakalim and valproate, albeit at higher concentrations. The data indicate that retigabine exerts potent broad spectrum activity making it an interesting candidate for treatment of drug resistant patients.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="full">Department of Pharmacology, Arzneimittelwerk Dresden GmbH, Corporate R&amp;D, ASTA Medica Group, Radebeul, Germany.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10604606</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0920-1211(99)00065-0</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0920-1211(99)00065-0"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0920-1211(99)00065-0"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0920-1211</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Epilepsy Res</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Anticonvulsants</api:keyword><api:keyword scheme="mesh">Calcium</api:keyword><api:keyword scheme="mesh">Carbamates</api:keyword><api:keyword scheme="mesh">Electrophysiology</api:keyword><api:keyword scheme="mesh">Epilepsy</api:keyword><api:keyword scheme="mesh">Hippocampus</api:keyword><api:keyword scheme="mesh">In Vitro Techniques</api:keyword><api:keyword scheme="mesh">Magnesium Deficiency</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Phenylenediamines</api:keyword><api:keyword scheme="mesh">Potassium Channels</api:keyword><api:keyword scheme="mesh">Rats</api:keyword><api:keyword scheme="mesh">Rats, Wistar</api:keyword><api:keyword scheme="mesh">gamma-Aminobutyric Acid</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Netherlands</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0920121199000650</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>24</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record><api:record format="native" id="881970" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10604606" last-modified-when="2021-01-19T17:54:58.01+00:00"><api:citation-count>35</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Retigabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester, D-23129) is a broad acting anticonvulsant currently undergoing phase II clinical trials. An opening effect on leakage conductance K+ channels, potentiation of GABA induced currents and a weak blocking effect on Na+ and Ca++ channels were previously reported. The goal of this study was to investigate whether retigabine is capable of blocking epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparations and whether the anti-burst activity can be related to the K+ channel opening effect. In the low Ca++ model, synaptic transmission is blocked and discharges evolve from ephaptically-coupled neurons. Compounds which directly interfere with the threshold for action potential induction via alteration of ion channel function (i.e. Na+ channel blocker) may alter the discharges, while compounds interfering with synaptic transmission are not active. Retigabine suppressed the discharges in a concentration-dependent manner. A significant reduction in frequency without effect on amplitude was observed after application of 1 microM, and a full block of all discharges after application of 25 microM. The opener of the ATP sensitive K+ channels cromakalim was also active. Application of 300 microM cromakalim yielded to a lower frequency with no effects on the amplitude of discharges. Treatment with phenytoin and carbamazepine resulted in a marked reduction in amplitude accompanied by a rise in frequency; only at higher concentrations was a full block observed. The effect of retigabine therefore differs from sodium channel blockers and can be related to the K+ channel opening effect. In the low Mg++ model, excitatory neurotransmission is augmented by reducing the Mg++ block of NMDA channels. This results in development of interictal-like epileptiform activity in area CA1 in isolated hippocampal slices. Treatment with retigabine 10 microM resulted in a significant reduction of the discharges, and discharges were fully blocked after application of 25 microM. Qualitatively similar effects were observed with cromakalim and valproate, albeit at higher concentrations. The data indicate that retigabine exerts potent broad spectrum activity making it an interesting candidate for treatment of drug resistant patients.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="DE"><api:line type="full">Department of Pharmacology, Arzneimittelwerk Dresden GmbH, Corporate R&amp;D, ASTA Medica Group, Radebeul, Germany.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0920-1211(99)00065-0</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0920-1211(99)00065-0"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0920-1211(99)00065-0"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1872-6844</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10604606</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0920-1211</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Epilepsy research</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Hippocampus</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Rats</api:keyword><api:keyword scheme="mesh">Rats, Wistar</api:keyword><api:keyword scheme="mesh">Epilepsy</api:keyword><api:keyword scheme="mesh">Magnesium Deficiency</api:keyword><api:keyword scheme="mesh">Calcium</api:keyword><api:keyword scheme="mesh">Phenylenediamines</api:keyword><api:keyword scheme="mesh">gamma-Aminobutyric Acid</api:keyword><api:keyword scheme="mesh">Carbamates</api:keyword><api:keyword scheme="mesh">Potassium Channels</api:keyword><api:keyword scheme="mesh">Anticonvulsants</api:keyword><api:keyword scheme="mesh">Electrophysiology</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">In Vitro Techniques</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>22</api:day><api:month>12</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record><api:record format="native" id="2631273" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1014127843" last-modified-when="2024-03-15T02:34:33.557+00:00"><api:citation-count>48</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>3</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Department of Pharmacology, Arzneimittelwerk Dresden GmbH, Corporate R&amp;D, ASTA Medica Group, Meißner Str. 35, D-01445 Radebeul, Germany</api:line><api:line type="city">Dresden</api:line><api:line type="state">Saxony</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0661656744.91</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Department of Pharmacology, Arzneimittelwerk Dresden GmbH, Corporate R&amp;D, ASTA Medica Group, Meißner Str. 35, D-01445 Radebeul, Germany</api:line><api:line type="city">Dresden</api:line><api:line type="state">Saxony</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01122735444.54</api:identifier></api:identifiers><api:author-types><api:author-type>corresponding</api:author-type></api:author-types></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0920-1211(99)00065-0</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0920-1211(99)00065-0"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0920-1211(99)00065-0"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10604606</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0896-6974</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/985477"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Epilepsy Research</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">3208 Medical Physiology</api:keyword><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="rcdc">Neurosciences</api:keyword><api:keyword scheme="hrcs-rac">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Neurological</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Anticonvulsants</api:keyword><api:keyword scheme="mesh">Calcium</api:keyword><api:keyword scheme="mesh">Carbamates</api:keyword><api:keyword scheme="mesh">Electrophysiology</api:keyword><api:keyword scheme="mesh">Epilepsy</api:keyword><api:keyword scheme="mesh">Hippocampus</api:keyword><api:keyword scheme="mesh">In Vitro Techniques</api:keyword><api:keyword scheme="mesh">Magnesium Deficiency</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Phenylenediamines</api:keyword><api:keyword scheme="mesh">Potassium Channels</api:keyword><api:keyword scheme="mesh">Rats</api:keyword><api:keyword scheme="mesh">Rats, Wistar</api:keyword><api:keyword scheme="mesh">gamma-Aminobutyric Acid</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>12</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>1.22</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record><api:record format="native" id="241045" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000084127100007" last-modified-when="2024-03-14T05:40:47.71+00:00"><api:citation-count>55</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000084127100007&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1872-6844</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">263LX</api:identifier><api:identifier scheme="pubmed">10604606</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0920-1211</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>EPILEPSY RESEARCH</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>in vitro</api:keyword><api:keyword>epilepsy</api:keyword><api:keyword>anticonvulsant</api:keyword><api:keyword>potassium channel</api:keyword><api:keyword>phenytoin</api:keyword><api:keyword>carbamazepine</api:keyword><api:keyword>cromakalim</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca&lt;SUP&gt;++&lt;/SUP&gt; and low Mg&lt;SUP&gt;++&lt;/SUP&gt; model in the hippocampal slice preparation</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record><api:record format="native" id="23875" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000084127100007" last-modified-when="2014-07-25T11:04:51.727+01:00"><api:citation-count>42</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dost</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rundfeldt</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0920-1211</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>EPILEPSY RES</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>in vitro</api:keyword><api:keyword>epilepsy</api:keyword><api:keyword>anticonvulsant</api:keyword><api:keyword>potassium channel</api:keyword><api:keyword>phenytoin</api:keyword><api:keyword>carbamazepine</api:keyword><api:keyword>cromakalim</api:keyword><api:keyword>LOW EXTRACELLULAR CALCIUM</api:keyword><api:keyword>TEMPORAL CORTEX SLICES</api:keyword><api:keyword>IN-VITRO</api:keyword><api:keyword>LOW MAGNESIUM</api:keyword><api:keyword>SYNAPTIC TRANSMISSION</api:keyword><api:keyword>RAT</api:keyword><api:keyword>NEURONS</api:keyword><api:keyword>EPILEPSY</api:keyword><api:keyword>D-23129</api:keyword><api:keyword>CROMAKALIM</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>53</api:begin-page><api:end-page>66</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>38</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Anticonvulsants</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Calcium</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Carbamates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Electrophysiology</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Epilepsy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Hippocampus</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">In Vitro Techniques</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Magnesium Deficiency</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Phenylenediamines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Potassium Channels</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Rats</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Rats, Wistar</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">gamma-Aminobutyric Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Hippocampus</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Rats</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Rats, Wistar</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Epilepsy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Magnesium Deficiency</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Calcium</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Phenylenediamines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">gamma-Aminobutyric Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Carbamates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Potassium Channels</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Anticonvulsants</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Electrophysiology</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">In Vitro Techniques</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3208 Medical Physiology</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Neurosciences</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Neurological</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Anticonvulsants</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Calcium</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Carbamates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Electrophysiology</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Epilepsy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Hippocampus</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">In Vitro Techniques</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Magnesium Deficiency</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Phenylenediamines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Potassium Channels</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Rats</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Rats, Wistar</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">gamma-Aminobutyric Acid</api:keyword><api:keyword origin="record-data" source="wos-lite">in vitro</api:keyword><api:keyword origin="record-data" source="wos-lite">epilepsy</api:keyword><api:keyword origin="record-data" source="wos-lite">anticonvulsant</api:keyword><api:keyword origin="record-data" source="wos-lite">potassium channel</api:keyword><api:keyword origin="record-data" source="wos-lite">phenytoin</api:keyword><api:keyword origin="record-data" source="wos-lite">carbamazepine</api:keyword><api:keyword origin="record-data" source="wos-lite">cromakalim</api:keyword><api:keyword origin="record-data" source="wos">in vitro</api:keyword><api:keyword origin="record-data" source="wos">epilepsy</api:keyword><api:keyword origin="record-data" source="wos">anticonvulsant</api:keyword><api:keyword origin="record-data" source="wos">potassium channel</api:keyword><api:keyword origin="record-data" source="wos">phenytoin</api:keyword><api:keyword origin="record-data" source="wos">carbamazepine</api:keyword><api:keyword origin="record-data" source="wos">cromakalim</api:keyword><api:keyword origin="record-data" source="wos">LOW EXTRACELLULAR CALCIUM</api:keyword><api:keyword origin="record-data" source="wos">TEMPORAL CORTEX SLICES</api:keyword><api:keyword origin="record-data" source="wos">IN-VITRO</api:keyword><api:keyword origin="record-data" source="wos">LOW MAGNESIUM</api:keyword><api:keyword origin="record-data" source="wos">SYNAPTIC TRANSMISSION</api:keyword><api:keyword origin="record-data" source="wos">RAT</api:keyword><api:keyword origin="record-data" source="wos">NEURONS</api:keyword><api:keyword origin="record-data" source="wos">EPILEPSY</api:keyword><api:keyword origin="record-data" source="wos">D-23129</api:keyword><api:keyword origin="record-data" source="wos">CROMAKALIM</api:keyword><api:keyword scheme="for" origin="issn-inferred">1103 Clinical Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Neurology &amp; Neurosurgery</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3209 Neurosciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">5202 Biological psychology</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">5203 Clinical and health psychology</api:keyword></api:keywords></api:all-labels><api:journal issn="0920-1211" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973848" title="Epilepsy Research"><api:records><api:record source-name="summary"><api:title>Epilepsy Research</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/671/relationships"/></api:object></api:result></api:response>